MedTrace Logo

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

NCT07082803 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-03-27

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas

Conditions

Interventions

DRUG

TLN-121

Specified dose on specified days.

DRUG

TLN-254

Specified dose on specified days.

DRUG

TLN-121

Specified dose on specified days.

Sponsors & Collaborators

  • Treeline Biosciences, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-23
Primary Completion
2030-09-30
Completion
2030-11-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07082803 on ClinicalTrials.gov